| P50 | author | Fernanda S. Tonin | Q42646503 |
| | Roberto Pontarolo | Q47562629 |
| | Fernando Fernandez-Llimos | Q47562653 |
| | Helena Hiemisch Lobo Borba | Q86645842 |
| P2093 | author name string | Astrid Wiens | |
| | Laiza M Steimbach | |
| | Cassio M Perlin | |
| | Maria L A Pedroso | |
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 | Q26768128 |
| | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis | Q26771458 |
| | New treatments for genotype 1 chronic hepatitis C - focus on simeprevir | Q26853138 |
| | Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients | Q27022569 |
| | The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. | Q27690869 |
| | The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 |
| | Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 |
| | Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials | Q33414720 |
| | Current and future therapies for hepatitis C virus infection | Q34036762 |
| | Elbasvir/Grazoprevir: First Global Approval | Q34516975 |
| | Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis | Q34533176 |
| | Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials | Q34570110 |
| | Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection | Q34607097 |
| | Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors | Q35146790 |
| | An assessment of the methodological quality of published network meta-analyses: a systematic review | Q35553233 |
| | Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study | Q35941510 |
| | Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis | Q36549805 |
| | Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons | Q37167644 |
| | Checking consistency in mixed treatment comparison meta-analysis | Q37705195 |
| | Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis | Q37937251 |
| | Protease inhibitors: silver bullets for chronic hepatitis C infection? | Q37989914 |
| | Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials | Q38034258 |
| | Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis | Q38047026 |
| | Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis. | Q38076444 |
| | Treatment decisions and contemporary versus pending treatments for hepatitis C. | Q38135774 |
| | Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection | Q38147910 |
| | Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis | Q38162979 |
| | New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. | Q38164242 |
| | Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir | Q38174251 |
| | The current state and future prospects of chronic hepatitis C virus infection treatment | Q38217350 |
| | Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis | Q38299183 |
| | Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis | Q38307721 |
| | A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus. | Q38454151 |
| | Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection | Q38462527 |
| | Assessing key assumptions of network meta-analysis: a review of methods | Q38520487 |
| | Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection | Q38522622 |
| | Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized trials | Q38599555 |
| | Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis. | Q38980577 |
| | Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial | Q40557598 |
| | Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea | Q40829783 |
| | Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial | Q41613250 |
| | Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection | Q41732349 |
| | Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach. | Q41757823 |
| | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study | Q42202640 |
| | Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial | Q42211649 |
| | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial | Q42211652 |
| | Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial | Q42224933 |
| | The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis | Q42224935 |
| | Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial | Q42225334 |
| | Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial | Q42242013 |
| | The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials | Q42270626 |
| | Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor | Q42282437 |
| | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial | Q42943536 |
| | Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study | Q42977630 |
| | Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial | Q42981494 |
| | Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan | Q43039581 |
| | The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses | Q85268718 |
| P433 | issue | 1 | |
| P921 | main subject | chronic hepatitis C | Q55779873 |
| P304 | page(s) | 1-14 | |
| P577 | publication date | 2016-10-19 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24 | |
| P478 | volume | 73 | |